COMPANY CONFIDENTIAL Welcome NIST Orbital Therapy, LLC.

Slides:



Advertisements
Similar presentations
Surface contour scanning system
Advertisements

Addition to Current Radiation Facility Program Some features are under development and will be subject to review by competent authorities (FDA, Notified.
Targeted Cancer Therapeutics, LLC Investor Presentation.
Energy deposition and neutron background studies for a low energy proton therapy facility Roxana Rata*, Roger Barlow* * International Institute for Accelerator.
Experience, Expertise and a Commitment to Excellence™
PULSE IMAGING, Inc. Company Overview 11/12/08 A World Without Skin Biopsies NON-INVASIVE EARLY SKIN CANCER DIAGNOSTIC SYSTEM.
D.G.Lewis Department of Medical Physics Velindre Cancer Centre Whitchurch, Cardiff RT-GRID: Grid Computing for Radiotherapy.
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 1 “RDA: better chemotherapy management” Investor Presentation April 2013.
CONTENTS ARE CONFIDENTIAL ORBITAL THERAPY, LLC Dedicated, self-shielded device for breast.
ClearVue TM Prone Position Breast Radiotherapy System.
The TrueBeam System ™ Clinic Name Presenter’s name Clinic location
Alamance Regional Cancer Center 2012
Quality Assurance: Manufacturer & Clinical Aspects  Alan Cohen, M.S. DABR  Paul Naine, MSc. MIPEM  Jim Schewe, PhD, DABMP Accuray Incorporated Elekta.
Radiotherapy for Brain Tumours What do I need to know? Dr Matthew Foote Radiation Oncologist Princess Alexandra Hospital Queensland.
WELCOME!!! FDA & MITA RT Meeting
ORBITAL THERAPY, LLC.
Quality & Regulatory Services, Inc. | 1 USER TRAINING Presented By Robert J. Morton, M.S. Certified Radiological Physicist President Quality.
ARDENT MEETING Andrej Sipaj June 13 th, ABOUT ME  Born and raised in Slovakia  Studied: BEng in Mechanical Engineering at UOIT, Canada MASc in.
EXHIBITORS. JL Shepherd & Associates is a provider of instruments for radiation detection instrumentation. The company was formed in 1967 and it principally.
Impacting Radiotherapy Safety and QA with Device Improvements Benedick A Fraass, PhD, FAAPM, FASTRO, FACR Allen S. Lichter Professor of Radiation Oncology.
به نام خداوند بخشایندۀ بخشایشگر
The Outreach Project “Helping NW companies access fund for R&D” Lesley Lambert General Engineering Research Institute Liverpool John Moores University.
The ESS vacuum team has overall responsibility for all technical vacuum systems used on the: Accelerator, Target and Neutron Scattering Instruments and.
ORBITAL THERAPY, LLC.
Starting a Medical Device Company: A Case Study Gerard L. Cote’, Ph.D. Department of Biomedical Engineering Texas A&M University.
STAR Park – STAR One Science, Technology and Advanced Research A member of The Texas State University System.
Better Outcomes Through Technology. Patient Specific QA Tools.
Varian Medical Systems By KJ Neish. History ›Originally incorporated in 1948 as Varian Associates, Inc. ›Changed name to Varian Medical Systems, Inc.
 The CyberKnife is a type radiation emitting machine used for the treatment of cancer. It emits radiation in high doses to millimeter precision. The.
The external beam radiotherapy and Image-guided radiotherapy (2)
Comparison of Rectal Dose Volume Histograms for Definitive Prostate Radiotherapy Among Stereotactic Radiotherapy, IMRT, and 3D-CRT Techniques Author(s):
CONTENTS ARE CONFIDENTIAL ORBITAL THERAPY, LLC Dedicated, self-shielded device for breast.
Comparison of Clinical Parameters for Proton Therapy in the United States Paige Summers, MS.
Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.
Greenwich Hospital Introduces New Radiation Therapy Program for Breast Cancer Greenwich Hospital’s Bendheim Cancer Center (Greenwich, CT) this week became.
Instructions: Developing a Presentation for Communicating with Board This PowerPoint template is meant to serve as a starting point for the development.
Board of Directors & Technical Committee Thursday, March 29, 2012 Data Management (Contract) Field Data Collection & Database Development Solution Presented.
FDA Public Meeting: Device Improvements to Reduce the Number of Under-doses and Misaligned Exposures from Therapeutic Radiation.
Institute for Advanced Radiation Oncology
About IntraOp Medical Co-founded in 1993 by Dr. Donald Goer Makers of the Mobetron, the first fully portable, self- shielding electron beam linear accelerator.
ORBITAL THERAPY, LLC.
NumaStore Nuclear Cardiology P.E.T. Nuclear Medicine Image Management Solution Mini-PACS for Nuclear Medicine Archiving and Data Management.
Medical Accelerator F. Foppiano, M.G. Pia, M. Piergentili
The Answer to Your Dosimetry Needs
CONFIDENTIAL Changing Environment Changing Environment “Should” (What Might Be) Mid-term Plan Product Roadmap Mid-term Plan Product Roadmap Long-term Plan.
COMPANY CONFIDENTIAL Design Review Meeting May 16, 2007 ORBITAL THERAPY, LLC.
ORBITAL THERAPY, LLC.
ESFRI & e-Infrastructure Collaborations, EGEE’09 Krzysztof Wrona September 21 st, 2009 European XFEL.
Somvilai Mayurasakorn, MD. Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang Mai University Somvilai Mayurasakorn, MD. Division.
ENLIGHT,12/2/20021 Health and Science, can CERN contribute? The Mission of CERN (1954): “The Organization shall provide for collaboration among European.
Introduction to Radiation Therapy
Photoneutron Distributions around 18 MV X-ray Radiotherapy Accelerators using Nuclear Track Detectors Fazal-ur-Rehman, H. Al-Ghamdi, M. I. Al-Jarallah.
Building the Best Team that Delivers and that Investors Love TEAMWORK MAKES THE DREAM WORK:
COUNTRY REPORT: PHILIPPINES Dr. Miriam Joy C. Calaguas.
Michael McMurphy Member of the Board of Directors, AREVA Med July 29, 2014 ~ Boston, MA.
Title of the presentation X-ray Therapy Systems Calibration Systems X-Ray Irradiators Image Guided Micro Irradiators Xstrahl Medical Systems Xstrahl Research.
MCS overview in radiation therapy
CONFIDENTIAL MATERIAL Michele Togno - II Annual ARDENT Meeting, Milan – October, 14 th D Ionization Chambers Array for Clinical Applications.
Research and Practical Conference “Accelerators and Radiation technologies for the Futures of Russia” September 2012, Saint-Petersburg Proton Radiation.
Kasey Etreni BSc., MRT(T), RTT, CTIC
Extending intracranial treatment options with Leksell Gamma Knife® Icon™ Key Statements from Customer Perspective by University Medical Centre Mannheim.
Radiological Sciences Department Ph.D., Paris-Sud 11 University
Press release Release of ISOgray Proton Treatment Planning System
Implementation of Object Spot Avoidance in Proton Pencil Beam Treatment on Whole Breast with Implant Metal Injector Peng Wang, PhD, DABR, Karla Leach,
Reducing Treatment Time and MUs by using Dynamic Conformal Arc Therapy for SBRT Breath-Hold Patients Timothy Miller, Sebastian Nunez Albermann, Besil Raju,
Objective Pain Measurement “ If you can’t measure it,
Volumetric Modulated Arc Therapy (VMAT) versus Intensity Modulated Radiation Therapy (IMRT) for Anal Carcinoma Heather Ortega, BSRT(T), CMD, Kerry Hibbitts,
Dosimetry of Alternative Techniques for Accelerated Partial Breast Irradiation Hanh Pham, B.S, CMD, Thanh Nguyen, BS, Christina Henson, MD, Salahuddin.
Average Dose-Volume Ratio
Presentation transcript:

COMPANY CONFIDENTIAL Welcome NIST Orbital Therapy, LLC

COMPANY CONFIDENTIAL AGENDA  Company & Product  Team  First Year Plans  Project Milestones

COMPANY CONFIDENTIAL COMPANY OVERVIEW  Massachusetts LLC entity established in 2007  Holding company DE S-corporation established in 2006  Registered in the State of MA in 2006  Supported by a $2M ATP/NIST grant & private funds  Equal equity split between 2 founders (Koshnitsky/Sliski)  Provisional patent filed in Q1, 2006  Utility patent application filed in Q3, 2006  2 additional provisional patents filed in Q3, 2007  3 man-years plus $30K invested to-date between partners Dedicated Radiotherapy Device for the Treatment of Breast Cancer

COMPANY CONFIDENTIAL External Radiation CLASSIC TX Current/Classic Treatment Technique  Patient in supine position (back)  Whole breast is treated  Lung and heart are effected  Multi-purpose linear accelerator used

COMPANY CONFIDENTIAL CURRENT TX OPTIONS Pros:  5 day treatment  Minimal dose to lung Cons:  Very select patient group(<1cm, deep seated)  Limited volumetric coverage – poor initial clinical results starting to surface clinical results starting to surface  No long-term data  Limited to one technique  Invasive  Infections due to invasive technique Pros:  Proven gold standard treatment  Complete volume treated  Non-invasive Cons:  6 week regiment  Dose to lung and heart  Hard to perform partial breast RT  Limited to technique used 2 extremes Very Little or All Balloon RTExternal RT

COMPANY CONFIDENTIAL Dedicated Radiotherapy Device for the Treatment of Breast Cancer   510K FDA clearance – predicate device is a linear accelerator*   Will NOT require clinical trials*   Patient in prone position (face down) to isolate the treatment site   Commercial accelerator sub-system (Siemens, Varian, other)   Maintain and improve on current standard of care (skin sparing, homogeneous dose, whole or partial breast RT)   Capable of delivering new emerging techniques (partial breast, accelerated, stereotactic radiosurgery, intensity modulated, etc)   Machine is self-shielding not requiring primary beam shielding   Compatible with existing, approved Treatment Planning SW from multiple vendors PRODUCT Source: NYU * Confirmed by an FDA expert

COMPANY CONFIDENTIAL PROCESS Set-Up

COMPANY CONFIDENTIAL PROCESS Beam-On

COMPANY CONFIDENTIAL PROCESS Treatment Delivery

COMPANY CONFIDENTIAL PROCESS Treatment Delivery

COMPANY CONFIDENTIAL PROCESS Treatment Delivery

COMPANY CONFIDENTIAL PROCESS Treatment Delivery

COMPANY CONFIDENTIAL PRODUCT Updated Design Table rotates 360 degrees Fixed gantry linear accelerator Self-shielding design

COMPANY CONFIDENTIAL PRODUCT Updated Design

COMPANY CONFIDENTIAL KEY BENEFITS Patient  Reduced dose to lung and heart – reduced long term complications  Better separation of target volume from critical structures – less adverse effects  Receive whole or partial breast irradiation – pathology specific treatment  Much less (or none) dose caused by scatter to eyes, skin and other organsClinic  Savings compared to purchase of a new linac > $1M  No bunker needed - savings >$1M  Free up space on already busy linac  Reduced planning & treatment time due to elimination of target motionPhysician  Ability to use advanced treatment techniques (IMRT, SRS, PBI)  Chose better treatment strategy depending on patient  Limit exposure to healthy organs

COMPANY CONFIDENTIAL REIMBURSEMENT BE at 125 pts (~15/d for 1YR)

COMPANY CONFIDENTIAL REIMBURSEMENT 10 pts/day for 1 YR BE ~ 1.7 yrs 20 pts/day for 1 YR BE < 1 yr

COMPANY CONFIDENTIAL SYSTEM BLOCK DIAGRAM

COMPANY CONFIDENTIAL DIGITAL CONTROL PANEL

COMPANY CONFIDENTIAL MammoKnife core patent filed and additional 2 patents submitted Awarded a $2M ATP/NIST Grant Applied for $300K SBIR Grant in collaboration with CTRC San Antonio (U of Texas) Legal entity and structure established Concept validated with leading scientists and physicians Management team with relevant experience and track record in place Core European team recruited and headquarters with service center established Medical Advisory Board headed by Dr. Formenti of NYU (pioneer of prone breast RT) Letters of Intent received from clinical collaborators European and US distribution and service organizations identified Component suppliers and production facilities identified and contacted KEY ACHIEVEMENTS

COMPANY CONFIDENTIAL IP Review 1 utility, 2 provisional filings 1 utility, 2 provisional filings 1 st covers prone, shielded, table or source rotating 1 st covers prone, shielded, table or source rotating 2 nd covers a prone table top for standard linacs for improved coverage 2 nd covers a prone table top for standard linacs for improved coverage 3 rd covers a shielded therapy machine generally 3 rd covers a shielded therapy machine generally

COMPANY CONFIDENTIAL Prone machine patent

COMPANY CONFIDENTIAL Shielded machine patent

COMPANY CONFIDENTIAL AGENDA  Company & Product  Team  First Year Plans  Project Milestones

COMPANY CONFIDENTIAL EMPLOYEES Jason Koshnitsky - CEO  16 years of experience in the area of radiation oncology radiology  Held Sr. Mgmt roles in American, European and Israeli companies including Guidant, Philips and Orex/Kodak  Co-founder of Bioropa, an internet portal for life science products  Lived in Italy, Belgium, Ukraine, Germany and Netherlands  B.S. in Medical Physics from State University of New York ESC  M.B.A. from SDA Bocconi (Milan, Italy). Alan Sliski - CTO  17 years of experience in radiotherapy device business  Co-founder of Photoelectron Corp, a Thermo Electron spin-off  Co-founder of Still River Systems, a start-up building proton therapy systems  Start-up experience in the Boston area doing electron beam lithography and magnetic measuring instruments  B.S. in physics from the University of Massachusetts in Amherst  24 patents issued, several pending and many publications in various fields Michael Dalterio – Experimental Physicist  xxxxxxx  xxxxxxxx

COMPANY CONFIDENTIAL ADVISORS Clinical/Scientific Participants & Advisors Silvia Formenti, M.D.  Professor and Chief Radiation Oncologist – New York University, NY, NY  Pioneer and key opinion leader in the area of prone breast radiotherapy Chandan Guha, Ph.D., M.D.  Associate Professor and Chief Radiation Oncologist – Montefiore Medical Center, Bronx, NY  Using prone treatments in his department Alan Alfieri, M.S.  Chief Radiobiologist and Associate Professor – Montefiore/Albert Einstein College of Medicine, Bronx, NY  30 years of research and business consulting experience in the area of radiation therapy Peter Biggs, Ph.D.  Chief Physicist of Photon Radiotherapy and Shielding – Mass General Hospital, Boston, MA  AAPM instructor on radiation shielding and protection  IEC committee member Niko Papanikolaou, Ph.D.  Professor and Director of Cancer Therapy Research Center at San Antonio, University of Texas  Expert in Monte Carlo simulations, oncology imaging and treatment planning software

COMPANY CONFIDENTIAL CONSULTANTS Clinical/Scientific Participants & Advisors Ken Hart, Ph.D.  >>>>>>>>>>>>>>>  >>>>>>>>>>>>>> Paul Sebring, M.E.  >>>>>>>>>>>>>> Paul Boisseau, Ph.D.  >>>>>>>>>>>>>>  >>>>>>>>>>>>>>>>> Peter Biggs, Ph.D.  Chief Physicist of Photon Radiotherapy and Shielding – Mass General Hospital, Boston, MA  AAPM instructor on radiation shielding and protection  IEC committee member Jacquelyn Yanch, Ph.D.  Professor of Nuclear Engineering, MIT  Monte Carlo simulation and analysis

COMPANY CONFIDENTIAL AGENDA  Company & Product  Team  First Year Plans  Project Milestones

COMPANY CONFIDENTIAL QUESTIONS from NIST  Status of the project as it starts  First year plans for the project  Project milestones go/no-go points  Updates or changes to the technical work plans – none to date  Company’s business status and update – LLC formation

COMPANY CONFIDENTIAL Q4/Q1 (07/08) Key Goals Generate first system specifications Overall configuration Functional specification Identify all applicable standards and regulations Set-up Monte Carlo model – first results Obtain linac monte carlo model Model basic shielding properties Generate first pass mechanical design Design for first full-scale model Design first shielding experiment Mechanical design and materials identified Equipment specified and test plan written

COMPANY CONFIDENTIAL System Features 4-6MV LINAC source from Siemens or Varian 4-6MV LINAC source from Siemens or Varian 20x20cm field size at isocenter 20x20cm field size at isocenter Multileaf collimator customized to this application, leaves Multileaf collimator customized to this application, leaves Rotating patient table Rotating patient table Optical patient alignment Optical patient alignment Granular shielding material for ease of transport, installation, decommissioning Granular shielding material for ease of transport, installation, decommissioning Integrated shielding Integrated shielding

COMPANY CONFIDENTIAL Monte Carlo system model Model 6MV accelerator Model 6MV accelerator Generate rough estimate of how much shielding is required around LINAC, collimator, beam dump Generate rough estimate of how much shielding is required around LINAC, collimator, beam dump Explore beam dump concepts: geometry, materials Explore beam dump concepts: geometry, materials

COMPANY CONFIDENTIAL Experimental shielding validation Design test configuration for different materials Design test configuration for different materials Choose detector for good sensitivity, some spectral information Choose detector for good sensitivity, some spectral information Order heavy stuff, build test fixture Order heavy stuff, build test fixture Measure results with local LINAC Measure results with local LINAC

COMPANY CONFIDENTIAL Near term technical focus Monte Carlo modeling of system elements Monte Carlo modeling of system elements Experimental validation of shielding Experimental validation of shielding Samples: solid lead, lead shot, tungsten powder Samples: solid lead, lead shot, tungsten powder Generate first-pass mechanical design Generate first-pass mechanical design Build a full scale model to visualize concepts Build a full scale model to visualize concepts

COMPANY CONFIDENTIAL Full scale model Build first pass mechanical design for visual concept introduction to customers, collaborators Build first pass mechanical design for visual concept introduction to customers, collaborators Include linac, collimator model, rotating table top Include linac, collimator model, rotating table top Aluminum framing, acrylic and plywood Aluminum framing, acrylic and plywood

COMPANY CONFIDENTIAL First pass mechanical design Incorporate linac, collimator, table top with rotation, cameras, beam dump Incorporate linac, collimator, table top with rotation, cameras, beam dump Present design concept to MDs Present design concept to MDs Generate 3D videos/images for presentations Generate 3D videos/images for presentations

COMPANY CONFIDENTIAL AGENDA  Company & Product  Team  First Year Plans  Project Milestones

COMPANY CONFIDENTIAL MAJOR TASKS YRS 1 & 2

COMPANY CONFIDENTIAL PROJECT TIMELINE

COMPANY CONFIDENTIAL PROJECT TIMELINE

COMPANY CONFIDENTIAL PROJECT TIMELINE